Company: CWAN
Filing Date: 2025-03-06
Form Type: S-4/A
Source: 0001193125-25-048570
Chunk: 80

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-06
Form: S-4/A
Chunk 80
---
 to provide voting instructions to your bank, brokerage firm or other nominee so that your vote will be counted on all matters. If you are a beneficial owner, you are invited to participate in the Special Meeting; however, you may not vote your shares at the Special Meeting unless you obtain a legal proxy from your bank, brokerage firm or other nominee that holds your shares, giving you the right to vote the shares at the Special Meeting. Revocation of Proxies Enfusion Stockholders of record may revoke their proxies at any time prior to the voting at the Special Meeting in any of the following ways:

| • |     | signing and delivering a new proxy relating to the same shares and bearing a later date than the original proxy; |

| • |     | sending a signed, written notice of revocation, which is dated later than the date of the proxy and states that                
 the proxy is revoked, to Enfusion, Inc., Attention: Legal Department, 125 South Clark Street, Suite 750, Chicago, IL 60603; or |

| • |     | participating in and voting during the virtual Special Meeting. Participation in the virtual Special Meeting will 
 not, however, in and of itself, constitute a vote or revocation of a prior proxy.                                 |

Enfusion beneficial owners may change their voting instruction only by following the directions received from their bank, brokerage firm or other nominee for changing their voting instructions. 48

Solicitation of Proxies

Enfusion will pay for the proxy solicitation costs related to the Special Meeting. In addition to sending and making available these materials,
some of Enfusion’s directors, officers and employees may solicit proxies in person by contacting Enfusion Stockholders by telephone or over the Internet. Enfusion Stockholders may also be solicited by press releases issued by Enfusion, postings
on Enfusion’s websites and advertisements in periodicals. None of Enfusion’s directors, officers or employees will receive additional compensation for their solicitation services. Enfusion has engaged Innisfree to assist in the
solicitation of proxies for the Special Meeting. Enfusion estimates that it will pay Innisfree a fee of approximately $20,000, plus reasonable out-of-pocket expenses.
Certain banking institutions, brokerage firms, custodians, trustees, nominees and fiduciaries who hold shares for the benefit of another party may solicit proxies for Enfusion. If so, they will mail proxy information to, or otherwise communicate
with, the beneficial owners of shares of Enfusion Common Stock held by them. En